Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B-Reference-Cited by-同舟云学术

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B

Published:2013-07-09 Issue:1 Volume:20 Page:15-24
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Windyga J.¹,Lissitchkov T.²,Stasyshyn O.³,Mamonov V.⁴,Rusen L.⁵,Lamas J. L.⁶,Oh M.-S.⁷,Chapman M.⁸,Fritsch S.⁸,Pavlova B. G.⁸,Wong W.-Y.⁷,Abbuehl B. E.⁸

Affiliation:

1. Institute of Hematology and Transfusion Medicine; Warsaw Poland

2. Specialized Hematological Hospital “Joan Pavel”; Sofia Bulgaria

3. State Institution “Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine”; Lviv Ukraine

4. Hematological Research Center; Moscow Russia

5. Prof. Dr. C. T. Nicolau National Institute for Transfusional Hematology; Bucharest Romania

6. Hospital Dr. Sotero del Rio; Santiago Chile

7. Global Clinical Research and Development; Baxter BioScience; Westlake Village CA USA

8. Global Clinical Research and Development; Baxter BioScience; Vienna Austria

Publisher

Wiley

Subject